| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 23.04 | -0.13 (-0.56%) | 15.43 - 26.30 | 809.2 thousand (Below Avg) |
Market data as of 4:00PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 23.26 |
|---|---|
| Previous Close | 23.17 |
| Day's Range | 22.74 - 23.43 |
| Market Cap | 3.1B |
| Avg Volume (10 Day) | 894.1K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.11 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Pass |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Incyte to Present at Upcoming Investor Conferences
Business Wire - Friday 05/03/2013 8:00 AM ET
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
Business Wire - Thursday 05/02/2013 3:37 PM ET
Incyte Reports First-Quarter 2013 Financial Results; Updates Shareholders on Key Clinical Programs
Business Wire - Thursday 05/02/2013 7:00 AM ET
Incyte Achieves $25 Million Milestone as c-MET Inhibitor INC280 Advances Into Phase II Development
Business Wire - Monday 04/29/2013 8:00 AM ET
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
Business Wire - Friday 04/19/2013 12:40 PM ET
| INCY | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 236.46% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | 9.42 |
| Company | Last | Change |
|---|---|---|
| Ambit Biosciences Corp | 6.75 | -8.66% |
| ARIAD Pharmaceuticals Inc | 16.67 | +1.21% |
| Fibrocell Science Inc | 5.00 | -- |
| Jazz Pharmaceuticals PLC | 58.36 | +0.07% |
| Medivation Inc | 47.53 | -1.57% |
Data is delayed by at least 15 min.